Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the p...
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Purpose
To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens.
Methods
ER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studie...
Alternative Titles
Full title
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820606
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820606
Other Identifiers
ISSN
0344-5704
E-ISSN
1432-0843
DOI
10.1007/s00280-019-03954-8
